830 INDEX
dermatophytes (Continued)
microscopic examination, 322, 333
polymerase chain reaction (PCR), 30
sample collection, 28–29,31–32, 334
trichograms, 44, 52
dermatophyte test medium (DTM), 28, 29, 323
dermatophytosis, 320–326
acantholytic, 321, 331
clinical features, 321,326–331
alopecia, 59, 60,82,321,326–328
claw/foot,330, 605, 606
exfoliative lesions, 62, 94
keratinization defects, 435, 454
diagnostics, 322–323,332–336
differential diagnosis, 177, 322
etiology/pathogenesis, 320
granulomatous, 321, 323, 329
signalment/history, 321
therapeutics, 323–325
treatment goals (CCATS, Moriello), 325–326
zoonotic,330–331, 730
dermoepidermal junction, 39
dermonecrotoxin, 144
Dermoscent Essential-6 spot-on, 650
DESseediethylstilbestrol
deslorelin, 341
desmogleins (Dsg1 and Dsg3), 188, 195
desmoplasia, 39
desmosomes, 187–188
desoxycorticosterone, 766
desquamation, 5,7, 9
Devon rex cat
hereditary hypotrichosis, 61
Malasseziadermatitis, 481, 589
squamous cell carcinoma, 673, 712
dexamethasone, 766
for autoimmune blistering diseases, 197
for eosinophilic granuloma complex, 355
for insect bites and stings, 247
for otitis, 550
for uveodermatologic syndrome, 693
dexamethasone suppression test
high-dose (HDDST), 399, 411
low-dose (LDDST), 398, 403, 411
Dexasoneseedexamethasone
Dexavetseedexamethasone
diabetes mellitus
clinical features, 338, 342
hyperadrenocorticism with, 409, 410, 412
partial diffuse alopecia, 61, 90
superficial necrolytic dermatosis and, 665, 668
diapedesis, 39
diascopy, 700, 710
diazepam, 767
dicloxacillin sodium, 767
Dicuralseedifloxacin
diet
for anal furunculosis/perianal fistula, 164
for anal sac disorders, 171
challenge and provocation trials, 289–290
food elimination, 288–289
for hypothyroidism, 421
forMalasseziadermatitis, 485
for nocardiosis and actinomycosis, 537
for pyoderma, 217
raw, 288
for superficial necrolytic dermatosis, 668
diethylstilbestrol (DES), 767
effects on hair coat, 339, 347
for sex hormone imbalances, 341
difloxacin,219, 768
Diflucanseefluconazole
dihydrostreptomycin, 515
dilated pore of Winer, 674, 675, 677, 678
dimenhydrinate, 768
dimethyl sulfoxide (DMSO), 624
diphenhydramine, 768
for atopic disease, 181
for cutaneous mucinosis, 624
for mast cell tumors, 497
diphenoxylate, 769
direct impression smears, 46,53–55
dirofilariasis, 701
dirty face syndrome (facial dermatitis) of Persian and
Himalayan cats, 62,104,435, 453
discoid lupus erythematosus (DLE), 467–472
clinical features, 67, 469,473–475
crusting and erosive lesions, 63, 111
pigmentation changes, 65, 130
course and prognosis, 472
diagnostics, 471
facial-predominant, 468, 469,473–475
generalized (GDLE), 468, 469, 471,475–476
signalment/history, 468
therapeutics, 471–472
see alsocutaneous lupus erythematosus
disinfectants,149, 150, 151
distemper, canine, 713
DLEseediscoid lupus erythematosus
DMSO (dimethyl sulfoxide), 624
doberman pinscher, 736–737
acne, 157
color dilution alopecia, 61,90, 434
cryptococcosis, 522
cutaneous adverse drug reactions, 273
deep mycoses, 522
hypothyroidism, 417
ichthyosis, 432
leproid granuloma, 512
melanocytic tumors, 673
pemphigoid complex, 190
primary seborrhea, 433
self-injurious dermatoses, 228, 235
vitiligo, 65
DOCA pivalateseedesoxycorticosterone
DOCPseedesoxycorticosterone